Literature DB >> 26423909

Myocardial interstitial remodelling in non-ischaemic dilated cardiomyopathy: insights from cardiovascular magnetic resonance.

Andrea Barison1,2, Chrysanthos Grigoratos3,4, Giancarlo Todiere3,5, Giovanni Donato Aquaro3.   

Abstract

Myocardial remodelling involves not only the myocytes, but also non-myocyte cells and the extracellular matrix, which constitutes around 6 % of the normal heart and includes fluid, collagen and glycoproteins. In non-ischaemic dilated cardiomyopathy (DCM), the cardiac interstitium increases as a result of diffuse interstitial (microscopic) fibrosis, post-necrotic replacement (macroscopic) fibrosis or myocardial oedema. The activation of the renin-angiotensin-aldosterone system is a major determinant of fibroblasts activation and collagen deposition, with the transforming growth factor β as the downstream signal mediator. Endomyocardial biopsy still represents the current reference method for interstitial and replacement myocardial fibrosis assessment, but cardiovascular magnetic resonance (CMR) allows in vivo detection of macroscopic fibrosis with post-contrast late enhancement imaging. Moreover, recent pre- and post-contrast T1 mapping techniques provide a quantitative estimation of myocardial interstitial remodelling, with potential diagnostic and prognostic clinical utility. Here, we review the pathophysiological mechanisms of myocardial interstitial remodelling in DCM, its non-invasive characterization with biomarkers and with CMR, as well as the most recent studies about their clinical utility.

Entities:  

Keywords:  Dilated cardiomyopathy; Fibrosis; Interstitium; Late enhancement; Magnetic resonance; Remodelling; T1 mapping; T2 mapping

Mesh:

Substances:

Year:  2015        PMID: 26423909     DOI: 10.1007/s10741-015-9509-4

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  133 in total

1.  Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.

Authors:  F Zannad; F Alla; B Dousset; A Perez; B Pitt
Journal:  Circulation       Date:  2000-11-28       Impact factor: 29.690

Review 2.  Serum collagen markers and heart failure.

Authors:  P J Lijnen; T Maharani; N Finahari; J S Prihadi
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2012-09

Review 3.  Structural and functional characterisation of cardiac fibroblasts.

Authors:  Patrizia Camelliti; Thomas K Borg; Peter Kohl
Journal:  Cardiovasc Res       Date:  2005-01-01       Impact factor: 10.787

4.  Mismatch between uniform increase in cardiac glucose uptake and regional contractile dysfunction in pacing-induced heart failure.

Authors:  Vincenzo Lionetti; Letizia Guiducci; Anca Simioniuc; Giovanni D Aquaro; Claudia Simi; Daniele De Marchi; Silvia Burchielli; Lorenza Pratali; Marcello Piacenti; Massimo Lombardi; Piero Salvadori; Alessandro Pingitore; Danilo Neglia; Fabio A Recchia
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-08-17       Impact factor: 4.733

5.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

6.  T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance: quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy.

Authors:  Fabian aus dem Siepen; Sebastian J Buss; Daniel Messroghli; Florian Andre; Dirk Lossnitzer; Sebastian Seitz; Marius Keller; Philipp A Schnabel; Evangelos Giannitsis; Grigorios Korosoglou; Hugo A Katus; Henning Steen
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-09-22       Impact factor: 6.875

7.  Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy.

Authors:  Andrea Rossi; Mariantonietta Cicoira; Luisa Zanolla; Rita Sandrini; Giorgio Golia; Piero Zardini; Maurice Enriquez-Sarano
Journal:  J Am Coll Cardiol       Date:  2002-10-16       Impact factor: 24.094

8.  Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy.

Authors:  Valentina O Puntmann; Tobias Voigt; Zhong Chen; Manuel Mayr; Rashed Karim; Kawal Rhode; Ana Pastor; Gerald Carr-White; Reza Razavi; Tobias Schaeffter; Eike Nagel
Journal:  JACC Cardiovasc Imaging       Date:  2013-03-14

9.  Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.

Authors:  Rudolf A de Boer; Dirk J A Lok; Tiny Jaarsma; Peter van der Meer; Adriaan A Voors; Hans L Hillege; Dirk J van Veldhuisen
Journal:  Ann Med       Date:  2010-12-28       Impact factor: 4.709

10.  Clinical utility and prognostic value of left atrial volume assessment by cardiovascular magnetic resonance in non-ischaemic dilated cardiomyopathy.

Authors:  Ankur Gulati; Tevfik F Ismail; Andrew Jabbour; Nizar A Ismail; Kishen Morarji; Aamir Ali; Sadaf Raza; Jahanzaib Khwaja; Tristan D H Brown; Emmanouil Liodakis; Arun J Baksi; Rameen Shakur; Kaushik Guha; Michael Roughton; Ricardo Wage; Stuart A Cook; Francisco Alpendurada; Ravi G Assomull; Raad H Mohiaddin; Martin R Cowie; Dudley J Pennell; Sanjay K Prasad
Journal:  Eur J Heart Fail       Date:  2013-03-08       Impact factor: 15.534

View more
  16 in total

1.  Role of double knockdown of tPA and MMP-9 on regulating the left ventricular function and remodeling followed by transverse aortic constriction-induced hypertrophic cardiomyopathy in mice.

Authors:  Pei-Hsun Sung; Sarah Chua; Kuan-Hung Chen; Cheuk-Kwan Sun; Yi-Chen Li; Chi-Ruei Huang; Chi-Wen Luo; Han-Tan Chai; Hung-I Lu; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2018-09-15       Impact factor: 4.060

Review 2.  Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction.

Authors:  Michele Correale; Pietro Mazzeo; Lucia Tricarico; Francesca Croella; Martino Fortunato; Michele Magnesa; Marco Amatruda; Simona Alfieri; Salvatore Ferrara; Vincenzo Ceci; Giuseppe Dattilo; Marco Mele; Massimo Iacoviello; Natale Daniele Brunetti
Journal:  Clin Drug Investig       Date:  2022-06-20       Impact factor: 2.859

Review 3.  The effect of obesity, hypertension, diabetes mellitus, alcohol, and sleep apnea on the risk of atrial fibrillation.

Authors:  Z Čarná; P Osmančík
Journal:  Physiol Res       Date:  2021-12-30       Impact factor: 2.139

Review 4.  Diagnostic and prognostic role of cardiac magnetic resonance in acute myocarditis.

Authors:  Chrysanthos Grigoratos; Gianluca Di Bella; Giovanni Donato Aquaro
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

Review 5.  Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions.

Authors:  Erik H Howell; Scott J Cameron
Journal:  Cardiol J       Date:  2016-09-26       Impact factor: 2.737

6.  Diffuse myocardial fibrosis and the prognosis of heart failure with reduced ejection fraction in Chinese patients: a cohort study.

Authors:  Fuhai Li; Mengying Xu; Yuyuan Fan; Yanyan Wang; Yu Song; Xiaotong Cui; Mingqiang Fu; Baozheng Qi; Xueting Han; Jingmin Zhou; Junbo Ge
Journal:  Int J Cardiovasc Imaging       Date:  2020-01-01       Impact factor: 2.357

Review 7.  Myocardial T1 and T2 Mapping: Techniques and Clinical Applications.

Authors:  Pan Ki Kim; Yoo Jin Hong; Dong Jin Im; Young Joo Suh; Chul Hwan Park; Jin Young Kim; Suyon Chang; Hye-Jeong Lee; Jin Hur; Young Jin Kim; Byoung Wook Choi
Journal:  Korean J Radiol       Date:  2017-01-05       Impact factor: 3.500

8.  Variability of cardiovascular magnetic resonance (CMR) T1 mapping parameters in healthy volunteers during long-term follow-up.

Authors:  Fabian Aus dem Siepen; Christian Baumgärtner; Matthias Müller-Henessen; Florian André; Daniel Messroghli; Marco Ochs; Johannes Riffel; Evangelos Giannitsis; Hugo A Katus; Matthias G Friedrich; Sebastian J Buss
Journal:  Open Heart       Date:  2018-02-24

Review 9.  Arrhythmic risk stratification by cardiac magnetic resonance tissue characterization: disclosing the arrhythmic substrate within the heart muscle.

Authors:  Aldostefano Porcari; Antonio De Luca; Chrysanthos Grigoratos; Federico Biondi; Giorgio Faganello; Giancarlo Vitrella; Gaetano Nucifora; Giovanni Donato Aquaro; Marco Merlo; Gianfranco Sinagra
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

10.  Molecular remodeling of Cx43, but not structural remodeling, promotes arrhythmias in an arrhythmogenic canine model of nonischemic heart failure.

Authors:  Jiajie Yan; Cheryl Killingsworth; Greg Walcott; Yujie Zhu; Silvio Litovsky; Jian Huang; Xun Ai; Steven M Pogwizd
Journal:  J Mol Cell Cardiol       Date:  2021-05-31       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.